Prolonged functional life span of artificial red cells in blood circulation by repeated methylene blue injections

References

• Chang TM. Nanobiotechnology for hemoglobin-based blood substitutes. Crit Care Clin. 2009;25:373–382.
   PubMed Web of Science ®Google Scholar
• Alayash AI. Blood substitutes: why haven't we been more successful? Trends Biotechnol. 2014;32:177–185.
   PubMed Web of Science ®Google Scholar
• Winslow RM. Cell-free oxygen carriers: scientific foundations, clinical development, and new directions. Biochim Biophys Acta. 2008;1784:1382–1386.
   PubMed Web of Science ®Google Scholar
• Sakai H, Sou K, Tsuchida E. Hemoglobin-vesicles as an artificial oxygen carrier. Meth Enzymol. 2009;465:363–384.
   PubMed Web of Science ®Google Scholar
• Sakai H. Overview of potential clinical applications of hemoglobin vesicles (HbV) as artificial red cells, evidenced by preclinical studies of the academic research consortium. JFB. 2017;8:10.
   Web of Science ®Google Scholar
• Matsuhira T, Kure T, Yamamoto K, et al. Analysis of dimeric αβ subunit exchange between PEGylated and native hemoglobins (α2β2 tetramer) in an equilibrated state by intramolecular ββ-cross-linking. Biomacromolecules. 2018;19:3412–3420.
   PubMed Web of Science ®Google Scholar
• Sakai H, Masada Y, Takeoka S, et al. Characteristics of bovine hemoglobin as a potential source of hemoglobin-vesicles for an artificial oxygen carrier. J Biochem. 2002;131:611–617.
   PubMed Web of Science ®Google Scholar
• Takeoka S, Teramura Y, Atoji T, et al. Effect of Hb-encapsulation with vesicles on H2O2 reaction and lipid peroxidation. Bioconjug Chem. 2002;13:1302–1308.
   PubMed Web of Science ®Google Scholar
• Chen G, Chang T. Dual effects include antioxidant and pro-oxidation of ascorbic acid on the redox properties of bovine hemoglobin. Artif Cells Nanomed Biotechnol. 2018;46:983–992.
   PubMed Web of Science ®Google Scholar
• Takeoka S, Ohgushi T, Sakai H, et al. Construction of artificial methemoglobin reduction systems in Hb vesicles. Artif Cells Blood Substit Immobil Biotechnol. 1997;25:31–41.
   PubMed Web of Science ®Google Scholar
• Takeoka S, Sakai H, Kose T, et al. Methemoglobin formation in hemoglobin vesicles and reduction by encapsulated thiols. Bioconjugate Chem. 1997;8:539–544.
   PubMed Web of Science ®Google Scholar
• Teramura Y, Kanazawa H, Sakai H, et al. Prolonged oxygen-carrying ability of hemoglobin vesicles by coencapsulation of catalase in vivo. Bioconjugate Chem. 2003;14:1171–1176.
   PubMed Web of Science ®Google Scholar
• Sakai H, Masada Y, Onuma H, et al. Reduction of methemoglobin via electron transfer from photoreduced flavin: restoration of O2-binding of concentrated hemoglobin solution coencapsulated in phospholipid vesicles. Bioconjugate Chem. 2004;15:1037–1045.
   PubMed Web of Science ®Google Scholar
• Sakai H, Li B, Lim WL, et al. Red blood cells donate electrons to methylene blue mediated chemical reduction of methemoglobin compartmentalized in liposomes in blood. Bioconjugate Chem. 2014;25:1301–1310.
   PubMed Web of Science ®Google Scholar
• Kettisen K, Bülow L, Sakai H. Potential electron mediators to extract electron energies of RBC glycolysis for prolonged in vivo functional lifetime of hemoglobin vesicles. Bioconjugate Chem. 2015;26:746–754.
   PubMed Web of Science ®Google Scholar
• Ghirmai S, Bülow L, Sakai H. In vivo evaluation of electron mediators for the reduction of methemoglobin encapsulated in liposomes using electron energies produced by red blood cell glycolysis. Artif Cells Nanomed Biotechnol. 2018;46:1364–1372.
   PubMed Web of Science ®Google Scholar
• Sakai H, Takeoka S, Nishide H, et al. Convenient method to purify hemoglobin. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:651–656.
   PubMed Web of Science ®Google Scholar
• Sakai H, Seishi Y, Obata Y, et al. Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days. Shock. 2009;31:192–200.
   PubMed Web of Science ®Google Scholar
• Sou K, Klipper R, Goins B, et al. Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. J Pharmacol Exp Ther. 2005;312:702–709.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, You GX, et al. Conjugation with 20 kDa dextran decreases the autoxidation rate of bovine hemoglobin. Artif Cells Nanomed Biotechnol. 2018;46:1436–1443.
   PubMed Web of Science ®Google Scholar
• Faivre B, Menu P, Labrude P, et al. Hemoglobin autooxidation/oxidation mechanisms and methemoglobin prevention or reduction processes in the bloodstream. Literature review and outline of autooxidation reaction. Artif Cells Blood Substit Immobil Biotechnol. 1998;26:17–26.
   PubMed Web of Science ®Google Scholar
• Jeong ST, Ho NT, Hendrich MP, et al. Recombinant hemoglobin(alpha 29leucine → phenylalanine, alpha 96valine → tryptophan, beta 108asparagine → lysine) exhibits low oxygen affinity and high cooperativity combined with resistance to autoxidation. Biochemistry. 1999;38:13433–13442.
   PubMed Web of Science ®Google Scholar
• Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013;9:242–249.
   PubMedGoogle Scholar
• Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005;79:1615–1619.
   PubMed Web of Science ®Google Scholar
• Bradberry SM. Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev. 2003;22:13–27.
   PubMedGoogle Scholar
• Peter C, Hongwan D, Küpfer A, et al. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56:247–250.
   PubMed Web of Science ®Google Scholar